Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) Given Average Recommendation of “Hold” by Analysts

Share on StockTwits

Tetraphase Pharmaceuticals Inc (NASDAQ:TTPH) has received an average rating of “Hold” from the nine brokerages that are covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have given a buy rating to the company. The average 1 year price target among brokerages that have issued a report on the stock in the last year is $61.60.

TTPH has been the subject of several recent analyst reports. HC Wainwright downgraded Tetraphase Pharmaceuticals from a “buy” rating to a “neutral” rating in a report on Tuesday, September 3rd. Needham & Company LLC reissued a “hold” rating on shares of Tetraphase Pharmaceuticals in a report on Sunday, August 11th. Finally, ValuEngine downgraded Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, October 2nd.

A number of institutional investors have recently made changes to their positions in the business. Royce & Associates LP lifted its holdings in Tetraphase Pharmaceuticals by 10.7% during the 1st quarter. Royce & Associates LP now owns 527,900 shares of the biopharmaceutical company’s stock valued at $707,000 after purchasing an additional 51,000 shares during the last quarter. Edmond DE Rothschild Holding S.A. lifted its holdings in Tetraphase Pharmaceuticals by 90.9% during the 1st quarter. Edmond DE Rothschild Holding S.A. now owns 210,000 shares of the biopharmaceutical company’s stock valued at $281,000 after purchasing an additional 100,000 shares during the last quarter. JPMorgan Chase & Co. lifted its holdings in Tetraphase Pharmaceuticals by 803.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 116,428 shares of the biopharmaceutical company’s stock valued at $56,000 after purchasing an additional 103,544 shares during the last quarter. Vanguard Group Inc. lifted its holdings in Tetraphase Pharmaceuticals by 7.4% during the 2nd quarter. Vanguard Group Inc. now owns 2,514,773 shares of the biopharmaceutical company’s stock valued at $1,208,000 after purchasing an additional 173,053 shares during the last quarter. Finally, Acadian Asset Management LLC lifted its holdings in Tetraphase Pharmaceuticals by 45.4% during the 1st quarter. Acadian Asset Management LLC now owns 560,225 shares of the biopharmaceutical company’s stock valued at $750,000 after purchasing an additional 174,939 shares during the last quarter.

Shares of NASDAQ TTPH traded up $0.03 during trading hours on Friday, hitting $3.83. The company had a trading volume of 30,667 shares, compared to its average volume of 98,911. The stock has a market capitalization of $10.06 million, a P/E ratio of -0.14 and a beta of 2.46. The company has a quick ratio of 3.95, a current ratio of 4.10 and a debt-to-equity ratio of 0.70. Tetraphase Pharmaceuticals has a 1-year low of $3.35 and a 1-year high of $54.40. The firm’s 50 day moving average is $1.42 and its 200-day moving average is $0.92.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings data on Thursday, August 8th. The biopharmaceutical company reported ($8.40) EPS for the quarter, missing the consensus estimate of ($7.60) by ($0.80). The company had revenue of $1.07 million during the quarter, compared to analyst estimates of $2.13 million. Tetraphase Pharmaceuticals had a negative net margin of 1,072.60% and a negative return on equity of 118.65%. On average, sell-side analysts predict that Tetraphase Pharmaceuticals will post -26.55 earnings per share for the current year.

About Tetraphase Pharmaceuticals

Tetraphase Pharmaceuticals, Inc, a biopharmaceutical company, develops various antibiotics for the treatment of serious and life-threatening multidrug-resistant infections. The company's lead product candidate is Xerava (eravacycline), a synthetic fluorocycline intravenous and IV antibiotic for use as a first-line empiric monotherapy to treat multidrug-resistant infections, including multidrug-resistant Gram-negative infections.

Read More: Conference Calls and Individual Investors

Analyst Recommendations for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Ramsdens  Sets New 52-Week High at $210.00
Ramsdens Sets New 52-Week High at $210.00
Standard Life Aberdeen  Given “Buy” Rating at Goldman Sachs Group
Standard Life Aberdeen Given “Buy” Rating at Goldman Sachs Group
BBA Aviation  Rating Lowered to Hold at HSBC
BBA Aviation Rating Lowered to Hold at HSBC
Beazley  Given Hold Rating at Canaccord Genuity
Beazley Given Hold Rating at Canaccord Genuity
JPMorgan Chase & Co. Lowers Cisco Systems  Price Target to $58.00
JPMorgan Chase & Co. Lowers Cisco Systems Price Target to $58.00
HML  Stock Crosses Above 50-Day Moving Average of $32.12
HML Stock Crosses Above 50-Day Moving Average of $32.12


 
© 2006-2019 Zolmax.